drugset / Trial / NCT00934921
Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran® ODT under non-fasting conditions in healthy, non-smoking, adult subjects.
Timeline
- Start
- 2003-02
- Primary completion
- 2003-02
- Completion
- 2003-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ondansetron | Other / unclassified | 8 mg | — |
Indications
No indication recorded.